Gazlouleh Manufacturing Company’s ticker has been halted due to the long list of its creditors. The exact amount of this company’s debt has not been clearly defined and it will be announced after its loss and profit amounts’ announcement. This company has experienced its golden age during 2001- 2005 when due to good diplomatic relations with foreign countries, it requested for a loan from the International Monetary Fund and was about to start projects on the improvement of water and waste water pipes. However, its wishes and dreams were blown away after the 2005 election. Furthermore, factors such as non-operating returns, receiving loans, reliance on tender sales, governmental organizations’ failure in debt payoff, previous weak management, etc., made these conditions worse. The only solution to save this company has been stated to be bankruptcy announcement. As a result, this company has submitted its bankruptcy petition to Shahid Beheshti Judicial Complex of Tehran and its ticker will not reopen until the court verdict has been passed.
Mehr Kam Pars Company released the audited report on its 12-month performance for the FY2014 ending March 21, 2015. With its 552 IRR bn capital, this company was able to recognize 221 IRR EPS which was accompanied by a significant raise of 10,950% compared to the last year. Its net profit faced a 100% increase to be 6,095 IRR bn and its gross profit was also 498 IRR bn with 100% growth. The operating profit ratio of this company reached 229 IRR bn by a 46% increase and its financial costs grew by 4% compared to the last year.
Tabas Processed Coal Company released its unaudited budget for the FY2015. With its 180 IRR bn capital, this company considered 775 IRR EPS while it had estimated 894 IRR EPS for the FY2014. As can be realized, the company’s earning ratio has reduced by 13%. Its net sales and income from service delivery has been estimated to be about 627 IRR bn which shows a 7% increase compared to the last year. Although its final cost has been estimated to grow 14%, its gross profit has been forecasted to be about 204 IRR bn which has fell by 3% compared to the last year. Furthermore, its operating profit has been estimated to suffer a 12% fall to be 171 IRR bn and its financial costs will grow and reach 12 IRR bn in the budget for the FY2015.
Azarab Company released its unaudited report for the FY2014. With its 1,000 IRR bn capital, this company recognized 310 IRR EPS which shows a 75% increase compared to the last year. Its sales and income of service delivery ratio went up by 20%; its final costs of the sold goods increased by 10%; and the statistics of its gross profit demonstrated a 71% growth compared to the previous year. Although the financial costs raised by 29%, its operating profit grew by 83%. Put these all together, investors are advised to seriously take this share into consideration.
There is a high possibility of 10 to 15 percent increase in drug prices by July in Iran, The CEO of Etla Alborz Investment Co., a pharmaceutical holding, mentioned in an interview. Although the percentage change could be different for various medicines, none of the pharmaceutical companies considered this growth in their FY2015 forecasted EPS. He also added that there are 35 active pharmaceutical companies listed in TSE and IFB with over 93 thousand IRR total assets. Pharmaceutical sector is ranked 11 among other industries in Iranian capital market by having2.5 percent of the total market cap. It’s noteworthy that the sector has a stable 10 to 15 percent profitably growth rate in the last 10 previous years.
Persian Gulf Petrochemical Industry Holding released its first audited budget for the fiscal year ending June 20, 2016 with 1839 EPS which was 12% less than the previous year. This company estimated the next year’s return ratio to be 14% less than the current year’s as 42,191,303 IRR. However, it forecasted the return resulting from investment sales to be 17% more than the current year’s as 3,750,000, relying on the return gained from selling Fajr Petrochemical Company’s shares. As a conclusion, its total income and operating profit in the FY2016 have been estimated to be 45,941,303 IRR and 45,589,666 IRR respectively which both reveal a 12% decrease compared to the last year.
With its 600,000,000,000 IRR capital, Shahid Ghandi Corporation Complex, a communication cables producer in Iran, released its audited financial statement ending March 2014 which realized 225 loss per share. It is so while this amount was 187 loss per share in the previous year with 300,000,000,000 IRR. This shows a 3% drop in the company’s gross profit and its operating profit was also 15% less than the last year’s. Although the products’ final cost decreased by 3%, it was counteracted by the 27% growth of its financial costs.
Isfahan Steel Co. spent a tough year. Despite the good production, the company could not cover its forecasted budget due to heavy recession in metals and steel market. The company had forecasted 500 IRR EPS for FY2014 which adjusted negatively to 65 IRR based on 9 months period performance. However, the company recognized 163 IRR EPS at the end of FY2014. Based on company’s reports, the company is suffering from the low demand in domestic markets but the cash export sales to countries such as Iraq, Oman, and Afghanistan reached more than 160 thousand tons in 2015. The company has predicted 85 IRR EPS for FY2015 and any boom in development and construction projects may double this number.
Iran Khodro’s surprise for shareholders
Iran khodro Company recognized 481 IRR earning per share in FY2014. This company, with almost $ 3.6B capital, has posted its unaudited performance report for FY2014 ended on 20th March. This is while Iran Khodro had recognized 96 IRR loss per share in FY2013, with $ 2.8 B capital. Iran Khodro ‘s net sales ,being $1.69 B in FY2013, surged 17 percent in FY2014.Also, Cost of goods went up by 14 percent in financial year 2014 and gross profit, with 22 percent rise , reached $659000.This company also experienced 29 percent increase in expenditures sum and operational profit, with 20 percent growth, reached $553 M.
Good Reopening for a pharmaceutical symbol
Darou Pakhsh Pharmaceutical Mfg. Company, whose ticker was halted in the stock exchange market due to its annual general assembly for FY2014 at 4899 IRR, was reopened after this company divided 650 IRR cash in its assembly. What was interesting about the reopening session for this pharmaceutical symbol was its 14 percent rise in price against the expected theoretical price, calculated at 4249 IRR, as it was transacted at 4850 IRR and continued to be positively traded at 5092 IRR and even experience buying queue with P/E rate of 4.32.